PMID- 26148597
OWN - NLM
STAT- MEDLINE
DCOM- 20160406
LR  - 20150707
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 11
IP  - 2
DP  - 2015 Apr-Jun
TI  - Autoantibodies in the sera of breast cancer patients: Antinuclear and anti-double 
      stranded DNA antibodies as example.
PG  - 341-4
LID - 10.4103/0973-1482.157314 [doi]
AB  - BACKGROUND: Inflammation and cell necrosis are one of the consequences that 
      accompany breast cancer. However, inflammation and cell necrosis are well known 
      to be involved in stimulation of cellular and humeral immunity. OBJECTIVES: The 
      aim of this study is to investigate the immune response to the inflammation that 
      accompanies cancer through measuring plasma concentration of antinuclear 
      antibodies (ANAs) and anti-double stranded deoxyribonucleic acid antibodies 
      (ADSDAs). MATERIALS AND METHODS: Thirty-five newly diagnosed breast cancer 
      patients were involved in this study from the Radiation Isotopes Center Khartoum 
      (RICK) compared to 18 age- and sex-matched control subjects. Intravenous blood 
      sample was obtained from each study subject and Enzyme Linked Immuno Sorbent 
      Assay (ELISA) technique was used to determine the concentration of the two 
      antibodies. RESULTS: Regarding the ANA concentration in the patients; the range 
      was 0.7-1.8 IU/ml, mean was 0.96, and the standard deviation (SD) was 0.25; while 
      the range of the concentration in the control subjects was 0.3-0.6 IU/ml, mean 
      was 0.47, and SD was 0.07. However, when the means of patients and controls were 
      compared, the difference was significant (P < 0.000). Concerning the result 
      anti-double stranded DNA (anti-dsDNA), its concentration range in the patients 
      was 2.6-151.9 IU/ml, the mean was 55.2, and SD was 25.6, while in healthy people 
      concentration range was 26.1-97.3 IU/ml, the mean was 50.3, and SD was 16.9. 
      There was no significant change between the patients and controls (P = 0.46). 
      CONCLUSION: The ANA concentration in the patients was significantly increased, 
      while there was no significant difference between the results of ADSDAs in the 
      patients and the control subjects.
FAU - Mohammed, Mohammed Elimam Ahamed
AU  - Mohammed ME
AD  - Scientific Services and Laboratories Unit, Nuclear Applications in Biological 
      Sciences Institute (NABSI), Sudan Atomic Energy Commission, Khartoum, Sudan; 
      Department of Chemistry, Faculty of Science, King Khalid University, Abha, Saudi 
      Arabia, .
FAU - Abdelhafiz, Khalid
AU  - Abdelhafiz K
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Antinuclear/blood/immunology
MH  - Autoantibodies/*blood/*immunology
MH  - Breast Neoplasms/*blood/*immunology/pathology
MH  - Case-Control Studies
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
EDAT- 2015/07/08 06:00
MHDA- 2016/04/07 06:00
CRDT- 2015/07/08 06:00
PHST- 2015/07/08 06:00 [entrez]
PHST- 2015/07/08 06:00 [pubmed]
PHST- 2016/04/07 06:00 [medline]
AID - JCanResTher_2015_11_2_341_157314 [pii]
AID - 10.4103/0973-1482.157314 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2015 Apr-Jun;11(2):341-4. doi: 10.4103/0973-1482.157314.